Coherus reports Q3 revenue miss and lowers full-year outlook
+2 new sources since this summary was written
Coherus Oncology reported third-quarter revenue of $14.27M, below the $15.98M consensus. On its earnings call, management reported LOQTORZI sales of $14M and set a full-year revenue outlook of $54M-$57M, with $15M expected in Q4. The company said it is targeting quarterly LOQTORZI revenue of $25 million to $30 million in 2027 to cover core costs.
Why it matters
The revised revenue outlook changes the near-term sales baseline for investors, while the company’s LOQTORZI target indicates the scale of sales management believes is needed to cover core costs. Coherus also reiterated combined 2026 operating expenses of $170 million to $175 million, keeping funding needs central to the outlook.
Key facts
- 1Coherus reported Q3 revenue of $14.27M, below the $15.98M consensus. investing.com
- 2Third-quarter LOQTORZI net sales were $14M, up 3% from the prior quarter and 25% from a year earlier. finance.yahoo.com
- 3Coherus set its full-year revenue outlook at $54M-$57M and expects a $15M quarter in Q4. finance.yahoo.com
- 4The company reiterated combined operating expenses of $170 million to $175 million for 2026. finance.yahoo.com
- 5Coherus estimates it needs quarterly LOQTORZI revenue of $25 million to $30 million to cover core costs and aims to reach that level in 2027. finance.yahoo.com
Open questions
- The materials disagree on Q3 EPS: material 1 reports -$0.20 matching estimates, while materials 2 and 3 report 25 cents per share or ($0.25), with material 2 citing a 22 cents loss estimate.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.